New hope for hard-to-treat lymphoma? early trial of LTZ-301 begins
Disease control
Recruiting now
This early-phase study tests a new drug called LTZ-301 in 42 adults with certain types of non-Hodgkin lymphoma that have not responded to at least two prior treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that …
Phase: PHASE1 • Sponsor: LTZ Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC